-
Loading metrics
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5
- Adrianna Latuszek,
- Yashu Liu,
-
Olav Olsen ,
Roles Supervision, Writing – original draft, Writing – review & editing
* E-mail: olav.olsen@regeneron.com
Affiliation Regeneron Pharmaceuticals, Inc., New York, NY, United States of America
⨯ - Randi Foster,
- Marc Cao,
- Irena Lovric,
- Ming Yuan,
- Nina Liu,
- Henry Chen,
- Qian Zhang,
- Hui Xiao,
- Carola Springer,
- George Ehrlich,
- Vishal Kamat,
-
Ashique Rafique,
Roles Formal analysis, Supervision, Writing – review & editing
Affiliation Regeneron Pharmaceuticals, Inc., New York, NY, United States of America
⨯ - Ying Hu,
- Pamela Krueger,
- Tammy Huang,
- William Poueymirou,
- Robert Babb,
- Michael P. Rosconi,
- Marc W. Retter,
- Gang Chen,
- Lori Morton,
- Brian Zambrowicz,
- Jingtai Cao,
- Carmelo Romano,
- [ ... ],
- William C. Olson
- [ view all ]
- [ view less ]
http://orcid.org/0000-0002-6583-209X
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5
- Adrianna Latuszek,
- Yashu Liu,
- Olav Olsen,
- Randi Foster,
- Marc Cao,
- Irena Lovric,
- Ming Yuan,
- Nina Liu,
- Henry Chen,
- Qian Zhang
x
- Published: May 8, 2020
- https://doi.org/10.1371/journal.pone.0231892